Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Danielle S Cha

Showing results (51-60 of 81) with videos related to

Pageof 9
Sort By:
Expert Opinion on Drug Safety|June 17, 2020
Safety and tolerability of IV ketamine in adults with major depressive or bipolar disorder: results from the Canadian rapid treatment center of excellenceNelson B Rodrigues, Roger S McIntyre, Orly Lipsitz, et al.
Therapeutic Advances in Chronic Disease|June 28, 2016
The prevalence and clinical characteristics associated with Diagnostic and Statistical Manual Version-5-defined anxious distress specifier in adults with major depressive disorder: results from the International Mood Disorders Collaborative ProjectRoger S McIntyre, Hanna O Woldeyohannes, Joanna K Soczynska, et al.
Expert Review of Neurotherapeutics|September 21, 2020
The emerging role of psilocybin and MDMA in the treatment of mental illnessHartej Gill, Barjot Gill, David Chen-Li, et al.
Journal of Affective Disorders|September 3, 2020
Changes in symptoms of anhedonia in adults with major depressive or bipolar disorder receiving IV ketamine: Results from the Canadian Rapid Treatment Center of ExcellenceNelson B Rodrigues, Roger S McIntyre, Orly Lipsitz, et al.
Psychiatry Research. Neuroimaging|January 28, 2023
Evaluating the neural substrates of effort-expenditure for reward in adults with major depressive disorder and obesityHartej Gill, Roger S McIntyre, Colin Hawco, et al.
CNS Spectrums|December 10, 2020
Effectiveness of intravenous ketamine in mood disorder patients with a history of neurostimulationNelson B Rodrigues, Ashley Siegel, Orly Lipsitz, et al.
Journal of Affective Disorders|October 11, 2016
Liraglutide promotes improvements in objective measures of cognitive dysfunction in individuals with mood disorders: A pilot, open-label studyRodrigo B Mansur, Juhie Ahmed, Danielle S Cha, et al.
Journal of Affective Disorders|December 26, 2016
A randomized, double-blind, placebo-controlled, crossover trial evaluating the effect of intranasal insulin on cognition and mood in individuals with treatment-resistant major depressive disorderDanielle S Cha, Michael W Best, Christopher R Bowie, et al.
Journal of Affective Disorders|July 5, 2021
Efficacy of ketamine and esketamine on functional outcomes in treatment-resistant depression: A systematic reviewJason Ng, Joshua D Rosenblat, Leanna M W Lui, et al.
Journal of Affective Disorders|June 23, 2021
Does pre-treatment functioning influence response to intravenous ketamine in adults with treatment-resistant depression?Roger S McIntyre, Orly Lipsitz, Leanna M W Lui, et al.
Pageof 9

Showing results (51-60 of 81) with videos related to

Sort By:
Pageof 9
Expert Opinion on Drug Safety|June 17, 2020
Safety and tolerability of IV ketamine in adults with major depressive or bipolar disorder: results from the Canadian rapid treatment center of excellenceNelson B Rodrigues, Roger S McIntyre, Orly Lipsitz, et al.
Therapeutic Advances in Chronic Disease|June 28, 2016
The prevalence and clinical characteristics associated with Diagnostic and Statistical Manual Version-5-defined anxious distress specifier in adults with major depressive disorder: results from the International Mood Disorders Collaborative ProjectRoger S McIntyre, Hanna O Woldeyohannes, Joanna K Soczynska, et al.
Expert Review of Neurotherapeutics|September 21, 2020
The emerging role of psilocybin and MDMA in the treatment of mental illnessHartej Gill, Barjot Gill, David Chen-Li, et al.
Journal of Affective Disorders|September 3, 2020
Changes in symptoms of anhedonia in adults with major depressive or bipolar disorder receiving IV ketamine: Results from the Canadian Rapid Treatment Center of ExcellenceNelson B Rodrigues, Roger S McIntyre, Orly Lipsitz, et al.
Psychiatry Research. Neuroimaging|January 28, 2023
Evaluating the neural substrates of effort-expenditure for reward in adults with major depressive disorder and obesityHartej Gill, Roger S McIntyre, Colin Hawco, et al.
CNS Spectrums|December 10, 2020
Effectiveness of intravenous ketamine in mood disorder patients with a history of neurostimulationNelson B Rodrigues, Ashley Siegel, Orly Lipsitz, et al.
Journal of Affective Disorders|October 11, 2016
Liraglutide promotes improvements in objective measures of cognitive dysfunction in individuals with mood disorders: A pilot, open-label studyRodrigo B Mansur, Juhie Ahmed, Danielle S Cha, et al.
Journal of Affective Disorders|December 26, 2016
A randomized, double-blind, placebo-controlled, crossover trial evaluating the effect of intranasal insulin on cognition and mood in individuals with treatment-resistant major depressive disorderDanielle S Cha, Michael W Best, Christopher R Bowie, et al.
Journal of Affective Disorders|July 5, 2021
Efficacy of ketamine and esketamine on functional outcomes in treatment-resistant depression: A systematic reviewJason Ng, Joshua D Rosenblat, Leanna M W Lui, et al.
Journal of Affective Disorders|June 23, 2021
Does pre-treatment functioning influence response to intravenous ketamine in adults with treatment-resistant depression?Roger S McIntyre, Orly Lipsitz, Leanna M W Lui, et al.
Pageof 9